A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 50 mg, 100 mg or Placebo When Coadministered With Rosuvastatin 10 mg or 20 mg in Subjects With Primary Hypercholesterolemia

NCT00249912 Phase 3 COMPLETED

The purpose of this study is to evaluate lapaquistat acetate, once daily (QD), taken alone or with rosuvastatin on cholesterol levels in treating patients with elevated cholesterol.

Details

Lead sponsor	Takeda
Phase	Phase 3
Status	COMPLETED
Enrolment	415
Start date	2005-10
Completion	2007-04

Conditions

• Hypercholesterolemia

Interventions

• Lapaquistat acetate and rosuvastatin
• Lapaquistat acetate and rosuvastatin
• Rosuvastatin

Primary outcomes

• Change from Baseline in Low Density Lipoprotein cholesterol — Week 24 or Final Visit

Countries

United States, Canada